memantine + sertraline

Memantine + sertraline is a combination of two pharmaceutical drugs used together, primarily investigated for the treatment of major depressive disorder (MDD), especially in cases resistant to standard therapy. Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, which modulates glutamatergic neurotransmission and has neuroprotective properties. Sertraline is a selective serotonin reuptake inhibitor (SSRRI) that increases synaptic serotonin levels by inhibiting its reuptake at presynaptic neurons. Preclinical and clinical studies suggest that co-administration may produce synergistic antidepressant effects, potentially through increased brain-derived neurotrophic factor (BDNF) levels in key brain regions such as the hippocampus and prefrontal cortex[1][3][4]. This combination has shown efficacy in reducing depressive symptoms more effectively than either drug alone, with a favorable safety profile over short-term use[3].